Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia
Open Access
- 1 January 1997
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 75 (2), 295-300
- https://doi.org/10.1038/bjc.1997.48
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Bone metastases and tumor-induced hypercalcemiaCurrent Opinion in Oncology, 1992
- BisphosphonatesDrugs, 1991
- BM 21.0955, a potent new bisphosphonate to inhibit bone resorptionJournal of Bone and Mineral Research, 1991
- Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): Respective role of kidney and boneJournal of Bone and Mineral Research, 1990
- PARATHYROID HORMONE-RELATED PROTEIN IN HYPERCALCAEMIA OF MALIGNANCYClinical Endocrinology, 1989
- Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro in rodents.Journal of Clinical Investigation, 1988
- Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronateBone, 1988
- THE PATHOGENESIS OF HUMORAL HYPERCALCAEMIA OF MALIGNANCYThe Lancet, 1987
- A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonateJournal of Bone and Mineral Research, 1986
- Mechanism of malignant hypercalcaemia in carcinoma of the breast.BMJ, 1985